Future directions for cardiovascular disease comparative effectiveness research: Report of a workshop sponsored by the national heart, lung, and blood institute

Mark A. Hlatky; Pamela S. Douglas; Nakela L. Cook; Barbara Wells; Emelia J. Benjamin; Kay Dickersin; David C. Goff; Alan T. Hirsch; Elaine M. Hylek; Eric D. Peterson; Véronique L. Roger; Joseph V. Selby; James E. Udelson; Michael S. Lauer

doi:10.1016/j.jacc.2011.12.057

Future directions for cardiovascular disease comparative effectiveness research: Report of a workshop sponsored by the national heart, lung, and blood institute

Mark A. Hlatky, Pamela S. Douglas, Nakela L. Cook, Barbara Wells, Emelia J. Benjamin, Kay Dickersin, David C. Goff, Alan T. Hirsch, Elaine M. Hylek, Eric D. Peterson, Véronique L. Roger, Joseph V. Selby, James E. Udelson, Michael S. Lauer

Medicine - Cardiology Division

Research output: Contribution to journal › Review article › peer-review

38 Scopus citations

Abstract

Comparative effectiveness research (CER) aims to provide decision makers with the evidence needed to evaluate the benefits and harms of alternative clinical management strategies. CER has become a national priority, with considerable new research funding allocated. Cardiovascular disease is a priority area for CER. This workshop report provides an overview of CER methods, with an emphasis on practical clinical trials and observational treatment comparisons. The report also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for evidence development to foster cardiovascular CER, and specific studies to address 8 clinical issues identified by the Institute of Medicine as high priorities for cardiovascular CER.

Original language	English (US)
Pages (from-to)	569-580
Number of pages	12
Journal	Journal of the American College of Cardiology
Volume	60
Issue number	7
DOIs	https://doi.org/10.1016/j.jacc.2011.12.057
State	Published - Aug 14 2012

Bibliographical note

Funding Information:
Drs. Cook, Wells, and Lauer are full-time employees of the National Heart, Lung, and Blood Institute (NHLBI). The views expressed in this manuscript do not necessarily represent the views of the NHLBI, National Institutes of Health, or any other government entity. Dr. Goff is a research consultant for and a data and safety monitoring board member for a clinical trial of a glucose-lowering medication marketed by Merck and Takeda. Dr. Hirsch has relationships with Pozen Medical, Merck, AstraZeneca, Abbott Vascular, Viromed, Summit Doppler, Novartis, and Cytokinetics. Dr. Hylek is on the scientific advisory board of Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Ortho-McNeil, and Pfizer. Dr. Selby was employed by Kaiser Permanente and is currently the Executive Director of the Patient Centered Outcomes Research Institute (PCORI); the opinions expressed in this paper do not necessarily reflect those of PCORI. Dr. Udelson has received research funding from the NHLBI. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Hlatky and Douglas cochaired the workshop.

Keywords

clinical trials
comparative effectiveness
research methods

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.jacc.2011.12.057

Find It

Find It at U of M Libraries

Cite this

Hlatky, M. A., Douglas, P. S., Cook, N. L., Wells, B., Benjamin, E. J., Dickersin, K., Goff, D. C., Hirsch, A. T., Hylek, E. M., Peterson, E. D., Roger, V. L., Selby, J. V., Udelson, J. E., & Lauer, M. S. (2012). Future directions for cardiovascular disease comparative effectiveness research: Report of a workshop sponsored by the national heart, lung, and blood institute. Journal of the American College of Cardiology, 60(7), 569-580. https://doi.org/10.1016/j.jacc.2011.12.057

Future directions for cardiovascular disease comparative effectiveness research: Report of a workshop sponsored by the national heart, lung, and blood institute. / Hlatky, Mark A.; Douglas, Pamela S.; Cook, Nakela L. et al.
In: Journal of the American College of Cardiology, Vol. 60, No. 7, 14.08.2012, p. 569-580.

Research output: Contribution to journal › Review article › peer-review

Hlatky, MA, Douglas, PS, Cook, NL, Wells, B, Benjamin, EJ, Dickersin, K, Goff, DC, Hirsch, AT, Hylek, EM, Peterson, ED, Roger, VL, Selby, JV, Udelson, JE & Lauer, MS 2012, 'Future directions for cardiovascular disease comparative effectiveness research: Report of a workshop sponsored by the national heart, lung, and blood institute', Journal of the American College of Cardiology, vol. 60, no. 7, pp. 569-580. https://doi.org/10.1016/j.jacc.2011.12.057

@article{4264d921042440c280a19b7603f7115f,

title = "Future directions for cardiovascular disease comparative effectiveness research: Report of a workshop sponsored by the national heart, lung, and blood institute",

abstract = "Comparative effectiveness research (CER) aims to provide decision makers with the evidence needed to evaluate the benefits and harms of alternative clinical management strategies. CER has become a national priority, with considerable new research funding allocated. Cardiovascular disease is a priority area for CER. This workshop report provides an overview of CER methods, with an emphasis on practical clinical trials and observational treatment comparisons. The report also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for evidence development to foster cardiovascular CER, and specific studies to address 8 clinical issues identified by the Institute of Medicine as high priorities for cardiovascular CER.",

keywords = "clinical trials, comparative effectiveness, research methods",

author = "Hlatky, {Mark A.} and Douglas, {Pamela S.} and Cook, {Nakela L.} and Barbara Wells and Benjamin, {Emelia J.} and Kay Dickersin and Goff, {David C.} and Hirsch, {Alan T.} and Hylek, {Elaine M.} and Peterson, {Eric D.} and Roger, {V{\'e}ronique L.} and Selby, {Joseph V.} and Udelson, {James E.} and Lauer, {Michael S.}",

note = "Funding Information: Drs. Cook, Wells, and Lauer are full-time employees of the National Heart, Lung, and Blood Institute (NHLBI). The views expressed in this manuscript do not necessarily represent the views of the NHLBI, National Institutes of Health, or any other government entity. Dr. Goff is a research consultant for and a data and safety monitoring board member for a clinical trial of a glucose-lowering medication marketed by Merck and Takeda. Dr. Hirsch has relationships with Pozen Medical, Merck, AstraZeneca, Abbott Vascular, Viromed, Summit Doppler, Novartis, and Cytokinetics. Dr. Hylek is on the scientific advisory board of Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Ortho-McNeil, and Pfizer. Dr. Selby was employed by Kaiser Permanente and is currently the Executive Director of the Patient Centered Outcomes Research Institute (PCORI); the opinions expressed in this paper do not necessarily reflect those of PCORI. Dr. Udelson has received research funding from the NHLBI. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Hlatky and Douglas cochaired the workshop. ",

year = "2012",

month = aug,

day = "14",

doi = "10.1016/j.jacc.2011.12.057",

language = "English (US)",

volume = "60",

pages = "569--580",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier Inc.",

number = "7",

}

TY - JOUR

T1 - Future directions for cardiovascular disease comparative effectiveness research

T2 - Report of a workshop sponsored by the national heart, lung, and blood institute

AU - Hlatky, Mark A.

AU - Douglas, Pamela S.

AU - Cook, Nakela L.

AU - Wells, Barbara

AU - Benjamin, Emelia J.

AU - Dickersin, Kay

AU - Goff, David C.

AU - Hirsch, Alan T.

AU - Hylek, Elaine M.

AU - Peterson, Eric D.

AU - Roger, Véronique L.

AU - Selby, Joseph V.

AU - Udelson, James E.

AU - Lauer, Michael S.

N1 - Funding Information: Drs. Cook, Wells, and Lauer are full-time employees of the National Heart, Lung, and Blood Institute (NHLBI). The views expressed in this manuscript do not necessarily represent the views of the NHLBI, National Institutes of Health, or any other government entity. Dr. Goff is a research consultant for and a data and safety monitoring board member for a clinical trial of a glucose-lowering medication marketed by Merck and Takeda. Dr. Hirsch has relationships with Pozen Medical, Merck, AstraZeneca, Abbott Vascular, Viromed, Summit Doppler, Novartis, and Cytokinetics. Dr. Hylek is on the scientific advisory board of Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Merck, Ortho-McNeil, and Pfizer. Dr. Selby was employed by Kaiser Permanente and is currently the Executive Director of the Patient Centered Outcomes Research Institute (PCORI); the opinions expressed in this paper do not necessarily reflect those of PCORI. Dr. Udelson has received research funding from the NHLBI. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Hlatky and Douglas cochaired the workshop.

PY - 2012/8/14

Y1 - 2012/8/14

N2 - Comparative effectiveness research (CER) aims to provide decision makers with the evidence needed to evaluate the benefits and harms of alternative clinical management strategies. CER has become a national priority, with considerable new research funding allocated. Cardiovascular disease is a priority area for CER. This workshop report provides an overview of CER methods, with an emphasis on practical clinical trials and observational treatment comparisons. The report also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for evidence development to foster cardiovascular CER, and specific studies to address 8 clinical issues identified by the Institute of Medicine as high priorities for cardiovascular CER.

AB - Comparative effectiveness research (CER) aims to provide decision makers with the evidence needed to evaluate the benefits and harms of alternative clinical management strategies. CER has become a national priority, with considerable new research funding allocated. Cardiovascular disease is a priority area for CER. This workshop report provides an overview of CER methods, with an emphasis on practical clinical trials and observational treatment comparisons. The report also details recommendations to the National Heart, Lung, and Blood Institute for a new framework for evidence development to foster cardiovascular CER, and specific studies to address 8 clinical issues identified by the Institute of Medicine as high priorities for cardiovascular CER.

KW - clinical trials

KW - comparative effectiveness

KW - research methods

UR - http://www.scopus.com/inward/record.url?scp=84864720888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864720888&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2011.12.057

DO - 10.1016/j.jacc.2011.12.057

M3 - Review article

C2 - 22796257

AN - SCOPUS:84864720888

SN - 0735-1097

VL - 60

SP - 569

EP - 580

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 7

ER -

Future directions for cardiovascular disease comparative effectiveness research: Report of a workshop sponsored by the national heart, lung, and blood institute

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this